CEL SCI Ownership

CVM Stock  USD 0.60  0.03  4.76%   
CEL SCI holds a total of 63.81 Million outstanding shares. Almost 86.63 percent of CEL SCI outstanding shares are held by general public with 2.91 (percent) owned by insiders and only 10.46 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
 
Shares in Circulation  
First Issued
2009-06-30
Previous Quarter
52 M
Current Value
54 M
Avarage Shares Outstanding
17.7 M
Quarterly Volatility
18.6 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Some institutional investors establish a significant position in stocks such as CEL SCI in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of CEL SCI, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
As of the 24th of November 2024, Dividend Yield is likely to grow to 0, while Dividend Payout Ratio is likely to drop (0.01). As of the 24th of November 2024, Common Stock Shares Outstanding is likely to grow to about 53.7 M, while Net Loss is likely to drop (35.6 M).
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CEL SCI Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

CEL Stock Ownership Analysis

The book value of the company was currently reported as 0.16. The company recorded a loss per share of 0.52. CEL SCI Corp last dividend was issued on the 28th of August 1996. The entity had 1:25 split on the 15th of June 2017. CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company was incorporated in 1983 and is headquartered in Vienna, Virginia. Cel-Sci Corp operates under Biotechnology classification in the United States and is traded on AMEX Exchange. For more info on CEL SCI Corp please contact Geert Kersten at 703 506 9460 or go to https://cel-sci.com.

CEL SCI Corp Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CEL SCI insiders, such as employees or executives, is commonly permitted as long as it does not rely on CEL SCI's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases CEL SCI insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

CEL SCI Outstanding Bonds

CEL SCI issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. CEL SCI Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most CEL bonds can be classified according to their maturity, which is the date when CEL SCI Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether CEL SCI Corp is a strong investment it is important to analyze CEL SCI's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CEL SCI's future performance. For an informed investment choice regarding CEL Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CEL SCI Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CEL SCI. If investors know CEL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CEL SCI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.52)
Revenue Per Share
0.001
Quarterly Revenue Growth
(0.63)
Return On Assets
(0.61)
Return On Equity
(2.50)
The market value of CEL SCI Corp is measured differently than its book value, which is the value of CEL that is recorded on the company's balance sheet. Investors also form their own opinion of CEL SCI's value that differs from its market value or its book value, called intrinsic value, which is CEL SCI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CEL SCI's market value can be influenced by many factors that don't directly affect CEL SCI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CEL SCI's value and its price as these two are different measures arrived at by different means. Investors typically determine if CEL SCI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CEL SCI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.